Anthem Biosciences Limited announced its standalone and consolidated financial results for the quarter ended June 30, 2026, following the Board of Directors meeting held on July 21, 2026. On a standalone basis, the company reported total income of Rs. 4,124.42 million and a net profit of Rs. 1,020.09 million for the current quarter. Comparing performance, standalone revenue from operations decreased by 34.18% sequentially (QoQ) from Rs. 5,825.01 million and decreased by 28.64% year-on-year (YoY) from Rs. 5,380.11 million. Meanwhile, standalone net profit decreased by 51.76% QoQ from Rs. 2,116.65 million and decreased by 31.23% YoY from Rs. 1,483.40 million.

Anthem Biosciences Limited is a prominent Bengaluru-based contract research, development, and manufacturing organization (CRDMO) operating across the drug discovery, development, and manufacturing value chain for both small molecules and biologics.